Key takeaways Satellite Symposium | Sunday 30th August, 12:30 - 13:30 Great debate on oral anticoagulation: Choosing the right treatment at initiation and knowing when to switch Start & Stay vs Case Spotlight: Case Spotlight: Time to Switch AF & Active...
More
Key takeaways Satellite Symposium | Sunday 30th August, 12:30 - 13:30 Great debate on oral anticoagulation: Choosing the right treatment at initiation and knowing when to switch Start & Stay vs Case Spotlight: Case Spotlight: Time to Switch AF & Active Malignancy AF & CKD • Renal function and body weight can shift over time • AF and cancer coexist often but joint - recheck dosing criteria regularly, not only at management is complex. baseline. • Switching DOAC DOAC or DOAC VKA without a clear indication is not recommended • A reduced dose of DOAC is not recommended, • CHA2DS2-VASc predicts stroke risk (2024 ESC Guidelines, Class III). unless patients meet DOAC-specific criteria (2024 reasonably well in cancer patients; ESC Guidelines, Class III, A). HAS-BLED does not. • Breakthrough stroke on anticoagulation warrants a full diagnostic work-up, • Not all evidence with reduced doses are equal: • Drug–drug interaction data with anti-cancer edoxaban has a wealth of evidence of efficacy and
Less
